Unijules Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 25.00 Cr
as on 19-04-2024
- Paid Up Capital ₹ 13.86 Cr
as on 19-04-2024
- Company Age 18 Year, 11 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 817.76 Cr
as on 19-04-2024
- Satisfied Charges ₹ 49.75 Cr
as on 19-04-2024
- Revenue -4.56%
(FY 2018)
- Profit -149.83%
(FY 2018)
- Ebitda -33.44%
(FY 2018)
- Net Worth -6.36%
(FY 2018)
- Total Assets -8.87%
(FY 2018)
About Unijules Life Sciences
- CIN/LLPIN
U52311MH2006PLC158928
- Company No.
158928
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2006
- Date of AGM
30 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Unijules Life Sciences Limited offer?
Unijules Life Sciences Limited offers a wide range of products and services, including Research and Development (R&D) Work, Product Development Research, Business Planning and Management, Business Consultant, Pain Relief Drugs & Pharmaceuticals, Pain Killers, Ayurvedic Medicine, Herbal Stress Relief Capsules Tablets, Ayurvedic Immunity Booster, Ayush Kwath.
Who are the key members and board of directors at Unijules Life Sciences?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Faiz Vali  | Managing Director | 16-Jan-2006 | Current |
| Murtaza Wardhawala | CFO | 20-Sep-2014 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Amit Chhabra | Director | 08-May-2017 | Current |
| Dharampal Bellani | Whole-Time Director | 03-Mar-2006 | Current |
| Hakimuddin Rizvi | Director | 02-Jun-2016 | Current |
Financial Performance of Unijules Life Sciences.
Unijules Life Sciences Limited, for the financial year ended 2018, experienced Minor drop in revenue, with a 4.56% decrease. The company also saw a substantial fall in profitability, with a 149.83% decrease in profit. The company's net worth dipped by a decrease of 6.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unijules Life Sciences?
In 2018, Unijules Life Sciences had a promoter holding of 59.97% and a public holding of 40.03%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Apr 2014 | ₹4.00 Cr | Open |
Punjab National Bank Creation Date: 26 Mar 2013 | ₹48.00 Cr | Open |
Yes Bank Limited Creation Date: 17 Sep 2012 | ₹10.00 Cr | Open |
How Many Employees Work at Unijules Life Sciences?
Unijules Life Sciences has a workforce of 76 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unijules Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unijules Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
